Bayer CropScience (506285) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
3 Nov, 2026Executive summary
Q2 FY27 revenue ₹12,507m vs ₹15,534m YoY; net profit ₹1,662m vs ₹1,527m.
H1 FY27 revenue ₹30,857m vs ₹34,680m; net profit ₹4,878m vs ₹4,314m.
Statutory auditors’ limited review found nothing indicating material misstatement or non-compliance with required disclosures.
Financial highlights
Q2 FY27 profit before tax ₹2,114m vs ₹2,003m YoY; total income ₹12,641m vs ₹15,672m.
H1 FY27 profit before tax ₹6,135m vs ₹5,355m; total income ₹31,880m vs ₹35,005m.
H1 other income included a ₹639m gain on divestment of formulated-product marketing rights.
Outlook and guidance
Business is seasonal; quarterly figures are not necessarily representative of full-year performance.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bayer CropScience
- CropScience scale expanded through merger, while one-offs weighed on reported earnings.506285
Q4 2003 - Drought drove a sharp earnings decline, while export and specialty-business growth offered offsets.506285Q4 2002
- PBT improved, but adjusted earnings faced portfolio, monsoon and pricing headwinds.506285Q4 2004
- PAT rose 41% as market share advanced to 16% despite a 12% industry decline.506285Q4 2005
- Profit rose as new products and seed distribution broadened growth plans; Thane closures triggered impairment.506285Q4 2006
- 15-month PAT was Rs 491m; Thane restructuring costs offset investment-sale gains.506285Q4 07/08
- PAT reached Rs. 944.59 million as new products met rising crop-protection demand.506285Q4 08/09
- Sales and PAT rose as new launches supported growth amid pricing and operational risks.506285Q4 09/10
- Revenue advanced and PAT grew modestly as innovation-led expansion met pricing and regulatory risks.506285Q4 10/11